Health Bulletin 20/February/2023

Published On 2023-02-20 10:32 GMT   |   Update On 2023-02-20 10:32 GMT
Advertisement

Here are the top health stories for the day:

NCDRC upholds Rs 10 lakh compensation to patient whose fingers got amputated due to gangrene

Opining that there was failure of duty of care, the National Consumer Disputes Redressal Commission (NCDRC) recently upheld the State Commission order holding Mata Chanan Devi Hospital guilty of negligence while providing treatment to the patient.

During the treatment, the patient developed gangrene in her hand during the ICU stay at the treating hospital and she later had to get the fingers of her hand amputated at Apollo Hospital. While considering the matter, the NCDRC bench has upheld the Rs 10 lakh compensation awarded by the State Commission.

Advertisement

For more details, check out the link given below:

Negligence In Care Of Diabetic Patient: NCDRC Upholds Rs 10 Lakh Compensation To Patient Whose Fingers Got Amputated Due To Gangrene

Malda Medical College to offer 14 new PG medical courses with 82 seats

Bringing good news to the Postgraduate medical aspirants in West Bengal, Malda Medical College and Hospital is soon going to commence PG medical courses in 14 new streams of medical science with an intake capacity of 82 seats.

Already the erstwhile Medical Council of India (MCI), now National Medical Commission (NMC) along with the State Health Department have given its permission in this regard, authorities informed Telegraph India.

For more details, check out the link given below:

Malda Medical College to offer 14 new PG medical courses with 82 seats


MSN Lab gets CDSCO panel nod for phase III CT of Elagolix Tablets

The drug major MSN Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the proposed Phase III clinical trial of the Elagolix Tablets 150mg & 200mg as per the protocol.

This came in line with the proposal presented by the drug maker MSN Laboratories for grant of permission for manufacturing and marketing of the drug Elagolix Tablets 150mg & 200mg.

For more details, check out the link given below:

MSN Lab Gets CDSCO Panel Nod For Phase III CT Of Elagolix Tablets

High court directs Kamineni Institute of Medical Sciences to refund excess fee

The division bench of the Telangana High Court issued contempt notices on Thursday to the management of Kamineni Institute of Medical Sciences at Narketpally for not initiating the refund of the excess tuition fee collected from the PG medical students of the batch 2016-19.

The bench comprising Chief Justice Ujjal Bhuyan and Justice N. Tukaramji was hearing a contempt case where some of the doctors, who had completed PG courses in the college, claimed that an excess amount of tuition fee was collected from the PG medical students of the academic session 2016-19.

For more details, check out the link given below:

High Court Directs Kamineni Institute Of Medical Sciences To Refund Excess Fee

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News